AACR 2026 Conference Intelligence

#AACR26 late breaking abstract on early data from 1st line Daraxonrasib monotherapy in #PancreaticCancer >90% disease control rate https://t.co/YIykE0HpCS @EileenMOReilly @GarridoLagunaMD @DrShubhamPant @RevMedicines https://t.co/1gwEhj6Xsy

RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we

Rick Pazdur at #AACR26! Makes a point for forgoing randomized trials & using external controls for highly effective agents like Daraxonrasib in #PancreaticCancer (for the 1st line trial, given 2nd line data is a home run). Is there really equipoise here given effect size? https://t.co/SQnYl1B2zU

#AACR26 Late breaking abstract Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic #PancreaticCancer (mPDAC) https://t.co/rZGr16nhKr @CentralParkWMD @DrShubhamPant @RevMedicines https://t.co/fmyuNIuQl1

Drug development is supposed to be linear. Build the drug → use the drug → resistance shows up → then figure out what to do next. Aaaand not what Revolution Medicines is doing. 🧬 At #AACR26 they disclosed RM-055, which honestly is a unique concept. Before daraxonrasib is https://t.co/CEpKpJnzoP

Mallika Singh @RevMedicines providing the audience at #AACR26 with the scientific underpinnings of KRas tricomplex inhibitors. After last week’s clinical data daraxonrasib is for sure on its way to become The molecule of this year‘s annual meeting. https://t.co/s2LaEgiKIy

What a time to be alive when I have to choose between attending Brian Wolpin’s talk on Daraxonrasib + chemo in 1st line #PancreaticCancer OR @RevMedicines talk on their preclinical asset RM-055 that overcomes KRAS inhibitor resistance, BOTH at the exact same time! #AACR26 https://t.co/5QddMaArZ9

This is the second abstract I was waiting for the whole @AACR #AACR26 #Daraxonrasib +GemNabPablitaxel in #mKRAS #PDAC in #FirstLine (GI-102 Platform) Phase I/II trial 40 pts ORR 58% DCR 90% 84% free of progresion at 6 months Ongoing Phase III 303 (Dara vs GemNab+/-Dara) https://t.co/tIfnZLMhJO

Waiting for two abstracts to be presented the whole @AACR #AACR26, this is one of them Just presented, #Daraxonrasib in #mKRAS #PDAC by @EileenMOReilly #Monotherapy in the #FirstLine 38 pts ORR 47% Time on tto 7.7m PFS immature Ongoing Phase III 303 (Dara vs GemNab+/-Dara) https://t.co/wUGkbo9rRk

GI-102 (Subprotocol C) – daraxonrasib + GnP in 1L mPDAC shows early signal 👇 #AACR26 🧬 Setting 1L metastatic PDAC, RAS-mutant cohort (n=40) 💊 Regimen Daraxonrasib (RAS(ON) inhibitor) + gemcitabine/nab-paclitaxel 👥 Study population Median age 69 ECOG 0-1: 100% Liver mets: https://t.co/gi2pZQJu4y https://t.co/qfqfLu3zD3

MSK gastrointestinal medical oncologist Dr. @EileenMOReilly speaks to a crowd about her late-breaking poster research on “Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic #pancreatic adenocarcinoma (mPDAC)” at #AACR26. @aacr https://t.co/f7OLDrS2bq

🧪 Daraxonrasib monotherapy in 1L RAS-mut mPDAC (#AACR2026, LB337) 📊 Phase 1/2 (n=40; evaluable n=35) 🔹 ORR 47–51% | DCR 92–97% 🔹 6-mo PFS 71% | OS 83% 🔹 ctDNA: 100% ↓ RAS VAF, 57% clearance 🔹 G≥3 TRAEs ~10% (rash, diarrhea, mucositis) 🔹 No G4/5 | dose mod 70% 🔗

⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send https://t.co/4UPSSqHCLC

Pancreatic cancer research at #AACR26: Dr. Brian Wolpin of @DanaFarber_Hale presents encouraging data on safety and efficacy from a small study combining the RAS inhibitor daraxonrasib with chemotherapy in patients with advanced #PancreaticCancer. @danafarber https://t.co/VXKNkTqeA4

$RVMD Cowen RVMD (Buy) - Revved Up for PDAC Domination #AACR26 RVMD presented further support for daraxonrasib's 1L use as both mono and in chemo combo. The 6mo PFS rates for mono/combo of 71/84% and 6mo OS of 83/90% track well above SoC chemo and we expect the gap to continue

Eileen O’Reilly’s daraxonrasib monoTx data in 1L PDAC - poster below to save y’all fighting through rows of people to get a view #aacr26 https://t.co/z4yW2apCBf

Daraxonrasib + gemcitabine/nab-paclitaxel in 1L RAS-mutated mPDAC shows manageable safety profile and encouraging early efficacy signals supporting the initiation of a global 3-arm phase 3 study 👉 https://t.co/O0G4bfoUB9 @OncoAlert #AACR2026

One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 https://t.co/ijyGOW6hmE https://t.co/kM9UKlZC5N

🧪 Daraxonrasib + ChT in 1L RAS-mut mPDAC (#AACR2026, LB407) 📊 Phase 1/2 (n=40) 🔹 ORR ~47–51% | DCR up to 97% 🔹 6-mo PFS 71% | OS 83% 🔹 ctDNA: 100% ↓ RAS VAF, 57% clearance 💥 Strong upfront signal with RAS(ON) inhibition 👉 Phase III ongoing (RASolute 303) 🔗

Incredible buzz at #AACR26 around the daraxonrasib data in #mKRAS #PDAC exciting signals & real hope for patients. Huge congratulations to @EileenMOReilly Chair of Scientific Advisory Board @CancerInstIRE on a standout presentation & tireless Q&A. Fantastic science and leadership https://t.co/fT6xx2rU0X

#AACR26 highlights #CommunityOnc: 1. #CM77T: PeriOP/PostOP Nivo in NSCLC 2. #TRUST: ROS1 1L NSCLC 3. RAS Inhibitor - Zoldonrasib in 2L and beyond NSCLC 4. RAS Inhibitor in Panc Ca - Daraxonrasib monotherapy in 1 L - Daraxonrasib + chemo in 1L #OncTwitter #MedX 1/6 https://t.co/UmaT0r69jO

New compound from @RevMedicines RM-055 disclosed at #AACR26 They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models. https://t.co/CQNDgXZwET

#AACR26 @AACR · Daraxonrasib just moved from "promising" to "new standard of care" territory Reading @dr_yakupergun's 1L mPDAC numbers alongside public disclosures by @RevolutionMeds in the days before #AACR26 opened, three data points organize the picture: 1/ Phase 3 RASolute

Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/qjRucVNcCs

@DavidHongMD @DrShubhamPant This algorithm is sooo... early April 2026!!! We recorded this discussion just days before press release of daraxonrasib but you can palpate @DrShubhamPant enthusiasm as we spent the last few minutes talking about where the RAS story is headed! 🙏🙏🙏

Heading to #AACR26 with my team that will be presenting several abstracts on daraxonrasib, novel pan-ras inhibitor ADT and next generation hyperbolic NAMPT inhibitor RPT @remedyplan @BasselElRayesMD @MNagasaka @NajeebAl_Hallak @ibrahimazaronc @MiguelTobonL @ElizaWBealMD https://t.co/RKBqyekI9V

Check out this Daraxonrasib data. It’s so beautiful I wanna cry. I am serious. #AACR26 #AACR2026 #PancreaticCancer https://t.co/FyAhD15WT7

I've learned so much about the regulatory side of drug development through this fellowship, especially with daraxonrasib currently under evaluation for accelarated approval. Thank you to @AACR & @US_FDA for hosting me at #AACR26! Looking foward to meeting again soon at the FDA. https://t.co/EtK1IRwXdo

#AACR26 #AACR2026 #RVMD I hope we hear more about using external controls for Daraxonrasib. There are people diagnosed today who could have a year or even two or more with their family, but for the rigid clinical trial and regulatory guidelines. PS: run do not walk to the https://t.co/fzH6w3i3it

Still lots of great #cancer science to be seen at #AACR26! Daraxonrasib in #pancreas cancer - poster now - huge crowd. Many other great posters to be seen! @revmedical @AACR @AACR_CEO https://t.co/dhEzbGTEqq

#AACR26 Daraxonrasib monotherapy, a RAS(ON) multi-selective inhibitor, is also making its mark In 1L mPDAC: ORR 47–51% DCR 92–97% 6-month PFS 71% 6-month OS 83% For a chemotherapy-free approach in pancreatic cancer, these results are highly encouraging https://t.co/IGddUvXP19 https://t.co/elwTv2DsqY https://t.co/qtKIZ1lnlb

🚨 Big early signal in 1L metastatic #PancreaticCancer at #AACR2026 Daraxonrasib (RAS(ON) multi-selective inhibitor) + gem/nab-paclitaxel in RAS-mutant mPDAC: ✅ ORR 58% ✅ DCR 90% ✅ 6-month PFS 84% ✅ Manageable safety #OncTwitter #MedTwitter #MedX @AACR @OncBrothers #MedEd https://t.co/nDWpIWd2zN

Daraxonrasib (RMC-6236), a promising pan-RAS inhibitor from @RevMedicines, vs docetaxel trial in KRAS mutant NSCLC is ongoing. Great to see Dr. @FSkoulidis at #AACR26 https://t.co/I5NYYTglZr

🚀 Big news from #AACR26! @RevMedicines RM-055: “RAS GAP on steroids” 🔥 Catalytic RAS(ON) inhibitor supercharges GTP hydrolysis, drives deep tumor regressions in G12 mutant PDAC/NSCLC/CRC models & overcomes daraxonrasib resistance 👏 #OncTwitter #gism #MedTwitter #MedX @AACR https://t.co/OnA2xIjF3q

market data suggests broad strength with $MSFT surging +1.46% and $AMZN up +0.66%, while $NVDA corrects -1.08% as focus shifts to upcoming clinical catalysts like Revolution Medicines' Daraxonrasib data.

@AlexTISYoung I think the better question is, can we use daraxonrasib in conjunction with first line therapy in CRC?

KRAS researchers keep working. Here they describe their pre-clinical work for their next generation inhibitors that overcome the resistance that this current generation of Daraxonrasib will eventually develop. https://t.co/Ctrk3RFEKU

🤯 Rev Med one step ahead of the game. Tackling RAS amplification-mediated daraxonrasib resistance prior to daraxonrasib approval. A great time to be a GI oncologist! #AACR26 https://t.co/NaxypHpTEm

🔥 Daraxonrasib plus Gem/Nab 1L #RAS mutated mPDAC @RevMedicines 💊 Mono ✔️ ORR 51% ✔️ DCR 97% ✔️ 6-mo PFS 84% 🩸clearance 61% 💊💉 Daraxonrasib+GemNab (n=40) ✔️ ORR 58% | DCR 90% ✔️ 6-mo PFS 84% 🩸 61% ☣️ RASH 👉🏼 Monotherapy may be enough in 1L #PDAC? 🤯 @AACR @OncoAlert https://t.co/65TJ6vmx4Y

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting $RVMD, #RevolutionMedicines, #RevMed https://t.co/EN0aW5QDIH

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/15HOeWlm0Q

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/uwUuuER8Ak

$NWBO Daraxonrasib seems like having great efficacy. How could Merck not acquire the company? Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC) https://t.co/aXsIxuHJd3 https://t.co/wEK5sl6ULt https://t.co/X37OFRk5wA

@christine_lovly @revmedical @AACR @AACR_CEO Behind every crowded poster are families waiting for options. Daraxonrasib represents hope for more humane outcomes.

#AACR26 late breaking abstract on early data from 1st line Daraxonrasib monotherapy in #PancreaticCancer >90% disease control rate https://t.co/YIykE0HpCS @EileenMOReilly @GarridoLagunaMD @DrShubhamPant @RevMedicines https://t.co/1gwEhj6Xsy

One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 https://t.co/ijyGOW6hmE https://t.co/kM9UKlZC5N

🧪 Daraxonrasib + ChT in 1L RAS-mut mPDAC (#AACR2026, LB407) 📊 Phase 1/2 (n=40) 🔹 ORR ~47–51% | DCR up to 97% 🔹 6-mo PFS 71% | OS 83% 🔹 ctDNA: 100% ↓ RAS VAF, 57% clearance 💥 Strong upfront signal with RAS(ON) inhibition 👉 Phase III ongoing (RASolute 303) 🔗

Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/qjRucVNcCs

Heading to #AACR26 with my team that will be presenting several abstracts on daraxonrasib, novel pan-ras inhibitor ADT and next generation hyperbolic NAMPT inhibitor RPT @remedyplan @BasselElRayesMD @MNagasaka @NajeebAl_Hallak @ibrahimazaronc @MiguelTobonL @ElizaWBealMD https://t.co/RKBqyekI9V

#AACR26 Daraxonrasib monotherapy, a RAS(ON) multi-selective inhibitor, is also making its mark In 1L mPDAC: ORR 47–51% DCR 92–97% 6-month PFS 71% 6-month OS 83% For a chemotherapy-free approach in pancreatic cancer, these results are highly encouraging https://t.co/IGddUvXP19 https://t.co/elwTv2DsqY https://t.co/qtKIZ1lnlb

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR : Top Trials from Day 2 RASolute 303 | RMC-6236-001 | CheckMate 77T | INFINITY | NeoZanHER | SHR-1316-III-303 | PLN-101095-ONC-101 | GBG-96-GeparDouze | NCT06131398 | DKY709A12101C #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter https://t.co/ol7y77fDl5

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/15HOeWlm0Q

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/uwUuuER8Ak

Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor. https://t.co/aslGbpWQI1

#AACR26 Zoldonrasib in previously treated KRAS G12D NSCLC with RR 52%, DCR 93%, time to response 1.4m, mDOR not reached with median follow up of 13.1m, mPFS 11.1m, and 73% of pts with ctDNA clearance. Fantastic presentation, exciting drug for our patients! https://t.co/xMQKLHOeXC

#AACR26 New frontiers in oncology 🚀 📌 Zoldonrasib (KRASG12D-ON) #NSCLC #KRASG12D 🗣️Dr. Reiss @ucdavis ✔️ ORR 52% ✔️ DCR 93%, mPFS 11.1m, OS NR ☣️ N/V 43%, diarrhea 30% 😀 New player #KRASG12D @RevMedicines 🗣️By @danieltanmd 👉🏼 Puts into context very nicely @OncoAlert @AACR https://t.co/nmeftCRPVx

Notice the % of tumor reduction is much deeper in zoldonrasib from $rvmd than $vstm. I suspect $vstm is more of an off inhibitor than on inhibitor.

Targeting the "undruggable" KRAS G12D just got a major boost at #AACR26! 🧬 Zoldonrasib (RMC-9805) data in pre-treated NSCLC presented by @riess_md 🔥 Efficacy: 52% ORR | 93% DCR ⏱️ Durability: mPFS 11.1 months (12-mo PFS: 48%) | mDOR: NE (95% CI: 8.3–NE) 🛡️ Safety: Favorable https://t.co/80OSYuZ8iq

Jonathan W. Riess, MD, of @UCD_Cancer presents data on first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D, mutation affecting approx. 61,000 new US patients/year w/ no approved targeted therapy. 📊Key https://t.co/rd0GmsnJTc

#AACR26 Zoldonrasib is a clean drug - toxicity profile is reassuring, with nausea, vomiting, and diarrhea seen but typically low grade, only 5% discontinuation rates due to toxicity. https://t.co/2CNOAHKabV

The KRAS inhibitor zoldonrasib showed effective and durable responses in patients with previously treated G12D-mutated non-small cell lung cancer, according to updated results from a phase I clinical trial reported at #AACR26 by Jonathan W. Riess, MD. https://t.co/HkCHizjFwE https://t.co/tMFe2uxyTb

$RVMD Zoldonrasib 2L NSCLC data @ AACR shows that there can be durability without mutational escape leading to rapid progression. Incrementally derisking of efficacy. Immature PFS & OS but trending. $VSTM's MOA is more powerful, & if they control AEs, this is undervalued at $600m https://t.co/GMRmkZeeFL

#AACR26 highlights #CommunityOnc: 1. #CM77T: PeriOP/PostOP Nivo in NSCLC 2. #TRUST: ROS1 1L NSCLC 3. RAS Inhibitor - Zoldonrasib in 2L and beyond NSCLC 4. RAS Inhibitor in Panc Ca - Daraxonrasib monotherapy in 1 L - Daraxonrasib + chemo in 1L #OncTwitter #MedX 1/6 https://t.co/UmaT0r69jO

Happening now at #AACR26 Clinical Trials Plenary: Jonathan Riess, MD (@riess_md @UCD_Cancer) shares preliminary safety and clinical activity of zoldonrasib (RMC-9805) forKRAS G12D non-small cell lung cancer. Key takeaways: Zoldonrasib (RMC-9805) is an oral, potent, https://t.co/CceWnMQxbl

🚨 Big news in KRAS G12D NSCLC! Can zoldonrasib (RMC-9805) finally deliver a breakthrough for this hard-to-treat mutation? 👉VIDEO: https://t.co/WrJqBrjFFB 🔥 Dr. Jonathan W. Riess @UCD_Cancer presents updated Phase 1 data at #AACR26: ✅ 52% confirmed ORR ✅ 93% DCR ✅ 11.1 https://t.co/WgEh84G1cM

Zoldonrasib treatment led to an objective response rate of 52%, a disease control rate of 93%, and a favorable safety and tolerability profile. #AACR26

elisrasib does not have a partner yet and zoldonrasib targets G12 D 4% of NSCLC and most common PDAC. https://t.co/pz80fJns0h

first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D https://t.co/COvqAYHVut

News: Zoldonrasib Deemed Safe, Effective in KRASG12D-mutant NSCLC https://t.co/VeoE2jeJnz https://t.co/9XJoyJOpkQ

⭐️ Excellent #AACR26 abstract breakdown of 🔑 abstracts for #CommunityOncology by the @OncBrothers ⭐️#CM77T ⭐️#TRUST ⭐️#RMC-9805-001 ⭐️#LB407 ⭐️#LB337 #Onctwitter #MedTwitter #MedX @AACR #gism #lcsm #FOAMed #MedEd #Oncology #KRAS #CancerResearch #Cancer #NSCLC https://t.co/0k4nJMH8XT

Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant #LungCancer https://t.co/GBKAheoY6S #AACR26 @CD_AACR https://t.co/tThVjoftmQ

KRAS G12D mutations remain an unmet need in #NSCLC. Phase I data for zoldonrasib: 📊 ORR 52% 📈 DCR 93% ⏳ PFS 11.1 months 🧪 Manageable toxicity (no grade 4/5 AEs) 🗣️ Presented by Jonathan W. Riess, MD (@riess_md) at #AACR26 Read more: https://t.co/xG8jO3xbhv https://t.co/88LzQbeECq

🧬 Early-phase data show zoldonrasib delivers promising efficacy and a favorable safety profile in heavily pretreated KRAS G12D–mutated NSCLC—a space with no approved targeted options. 📊 Read more ➡️ https://t.co/RtbyMywynM #LungCancer #NSCLC #KRAS #PrecisionOncology

2/4: Revolution Medicines to present updated Phase 1 zoldonrasib (KRAS G12D) NSCLC data at AACR; ORR 52% in selected cohort | View: The abstracted AACR update shows high ORR/DCR and tolerable safety at the RP2D, supporting… $RVMD $XBI $IBB https://t.co/yEKOT2LbjZ

Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS G12D-mutated non-small cell lung cancer, according to a phase I study. #AACR26 https://t.co/H0T2J7rsRu

Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer https://t.co/ff3CqPLUYh https://t.co/LjrKPi2GTA

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR Top Trials from Day 4 RMC-9805-001 | CAR-PRISM | CLOVER | INFINITY | D3S-001-100 | NCI-2018-01297 | CheckMate 77T | BP42675 | SHR-1316-III-303 | NCT06237881 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL https://t.co/9P4Lis53eX

🫁 Zoldonrasib showed “durable clinical efficacy” in patients with previously treated KRAS G12D NSCLC, according to an updated analysis of an ongoing phase 1 study presented at #AACR26 by @riess_md of @UCD_Cancer. ➡️ Read more: https://t.co/hvtuhVqYuE #lcsm #NSCLC #AACR2026 https://t.co/W4Phhoq1hV

🧬 Revolution Medicines is putting KRAS G12D NSCLC firmly into the targeted therapy conversation. https://t.co/5uuPq4laib At AACR 2026, updated Phase 1 data for zoldonrasib showed encouraging activity in patients with previously treated KRAS G12D non-small cell lung cancer, a https://t.co/5BIVM6WYqy

@Larvol @AACR @StephenVLiu @PatrickHwuMD @drgandara @GIMedOnc @ilyassahinMD 28K views for RMC-9805-001 at AACR indicate serious clinical interest. The oncology community does not generate this level of engagement without solid efficacy signals. Safety data remains the key question.

Zoldonrasib Displays Early Safety, Efficacy in Pretreated KRAS G12D–Mutated NSCLC https://t.co/Hx1QNAOSyt #aacr26

@StephenVLiu @riess_md @AACR Woohoo !! Shoutout to @riess_md . He was my Dr while I was on RMC-9805 last year at @ucdavis before I moved the trial closer to my home.

@danieltanmd @nccsingapore discusses why KRAS G12D is NOT just "the next G12C" & why zoldonrasib matters #AACR26. KRAS G12D is biologically distinct from G12C: ▪️ More common in people without tobacco exp ▪️ Lower TMB & PD-L1 expression ▪️ Less "immunogenic", fewer CD8+ T cells https://t.co/Mm4PYDVdmk

🚨 @AACR Press Conference 1 Highlights from #AACR26 dropping soon! 📹 https://t.co/JmiZvXBOAW Moderated by Jayesh Desai, MD (Peter MacCallum Cancer Centre) Featuring: 🔬 Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With https://t.co/PN9o9Ihk9a

Incredibly clean safety profile for Zoldonrasib (KRAS G12D)! @RevMedicines @AACR #AACR26 https://t.co/kSw5NRs7Ox

@DrRishabhOnco @AACR @ASCO Do you think Zoldonrasib would be standard of care for G12D soon ?

@Aiims1742 @CD_AACR This is an exciting advancement for KRAS G12D-mutant lung cancer treatment! The development of targeted therapies like zoldonrasib marks a significant step forward, given the challenges these mutations have historically posed. Are there insights on the long-term efficacy or

@StephenVLiu @DrPaulyDeSantis @riess_md @AACR @grok @BRicciutiMD @Annals_Oncology So is this data for RMC9805 + Keytruda ?

@MichaelMayMD Impressive results for Zoldonrasib! The high activity combined with a Grade 1 AE profile is a game-changer for #NSCLC. That level of tolerability opens so many doors for future G12D combinations. Exciting times ahead for precision oncology

🧬⚡ Breakthrough KRAS Data @RevMedicines reports promising zoldonrasib data, advancing targeted therapy in hard-to-treat cancers. 👉 https://t.co/ClQMTFNkEX #Oncology #ClinicalTrials #PrecisionMedicine https://t.co/CSvnjDp8Im

@DrMirallas @ucdavis @RevMedicines @danieltanmd @OncoAlert @AACR Mesmerizing results for Zoldonrasib emerging in the #KRASG12D space, particularly with an ORR of 52% and DCR of 93%. As a scientist, my curiosity is piqued regarding the specific patient demographics and any biomarker stratification. What are your thoughts, Dr. Mirallas, on the

#AACR26 In CheckMate 77T, ctDNA clearance much more likely with perioperative nivolumab (75% vs 46%) and clearance with nivo more strongly associated with pCR (70%) than placebo (18%). Those who do not clear ctDNA have virtually no chance for pCR. Escalation strategy here? https://t.co/glPt4MlJfa

Dr. Tina Cascone at #AACR26 with a fantastic, data-rich update on genomic markers and ctDNA dynamics from CheckMate 77T. Already an approved SOC after demonstrating increase in pCR and EFS with addition of perioperative nivolumab to neoadjuvant chemo for resectable NSCLC. https://t.co/RIBPNasFJl

💥 Minisymposium: Aiming for a Cure!🎯 @AACR #AACR26 🗣️ Dr. Cascone @UTMDAnderson 📌 Checkmate 77T: Perioperative Nico + chemo in stage IIA-IIIB in #NSCLC ✔️ EFS was longer if =>1 Co alteration in STK11, KEAP1, SMARCA4 and/or CDKN2A ✔️ EFS 60 vs 30% with HR 0.40 @OncoAlert https://t.co/Aq8VRFjSIq

Based on the initial results from the CheckMate 77T trial, @us_fda approved perioperative nivolumab for the treatment of resectable non-small cell lung cancer in 2024. At #AACR26, Dr. Tina Cascone presented additional findings derived from biomarker analyses. (1/2) https://t.co/It0dItbAZr

#AACR26 highlights #CommunityOnc: 1. #CM77T: PeriOP/PostOP Nivo in NSCLC 2. #TRUST: ROS1 1L NSCLC 3. RAS Inhibitor - Zoldonrasib in 2L and beyond NSCLC 4. RAS Inhibitor in Panc Ca - Daraxonrasib monotherapy in 1 L - Daraxonrasib + chemo in 1L #OncTwitter #MedX 1/6 https://t.co/UmaT0r69jO

ctDNA + genomics finally refining perioperative IO in resectable NSCLC 👀 #AACR26 CheckMate 77T – exploratory biomarker analysis 🧬 Population Resectable stage IIA–IIIB (N2) NSCLC NIVO + chemo → surgery → adjuvant NIVO vs placebo 🧪 Key genomic group KEAP1 / STK11 / CDKN2A https://t.co/Bw22U8pBsO https://t.co/qfqfLu3zD3

Dr. Tina Cascone @UTMDAnderson shared a subgroup analysis from the phase 3 CheckMate77T study of perioperative nivolumab in resectable #NSCLC. Genomic markers and ctDNA levels may have a role in predicting outcomes and guiding treatment but require follow up studies. #AACR26 https://t.co/LSYgJOEImP

⭐️ Excellent #AACR26 abstract breakdown of 🔑 abstracts for #CommunityOncology by the @OncBrothers ⭐️#CM77T ⭐️#TRUST ⭐️#RMC-9805-001 ⭐️#LB407 ⭐️#LB337 #Onctwitter #MedTwitter #MedX @AACR #gism #lcsm #FOAMed #MedEd #Oncology #KRAS #CancerResearch #Cancer #NSCLC https://t.co/0k4nJMH8XT

At #AACR26, Tina Cascone shares, “ Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T”. Explore related translational work in #JITC, where Brian S. Henick et al evaluate neoadjuvant atezolizumab and https://t.co/2WtznCulhm

👉AACR 2026 👉checkmate 77t 👉benefit with perioperative nivolumab across mutation subtypes. EFS similar with nivo when KEAP1, STK11, SMARCA4, and/or CDKN2A altered #AACR2026 #LungCancer #Immunotherapy #Oncology #ClinicalTrials https://t.co/K9pSurWah3

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR Top Trials from Day 4 RMC-9805-001 | CAR-PRISM | CLOVER | INFINITY | D3S-001-100 | NCI-2018-01297 | CheckMate 77T | BP42675 | SHR-1316-III-303 | NCT06237881 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL https://t.co/9P4Lis53eX

At #AACR26, Dr. Tina Cascone will present data from CheckMate 77T, exploring clinical outcomes by genomic markers and ctDNA dynamics in resectable non-small cell lung cancer (#NSCLC). Learn more: https://t.co/JctSJCnTjE https://t.co/4k0UDuAKP0

@AACR : Top Trials from Day 2 RASolute 303 | RMC-6236-001 | CheckMate 77T | INFINITY | NeoZanHER | SHR-1316-III-303 | PLN-101095-ONC-101 | GBG-96-GeparDouze | NCT06131398 | DKY709A12101C #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter https://t.co/ol7y77fDl5

🧬🫁 CheckMate 77T is starting to show that perioperative nivolumab may not be a one-size-fits-all strategy in resectable NSCLC. https://t.co/jWUrCwbeKQ A new biomarker analysis suggests that ctDNA dynamics and tumor genomics may help identify which patients gain the most from https://t.co/n4MkYPIHJC

CART in smoldering myeloma. Hopefully they will do MGUS next. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial | Nature Medicine https://t.co/zPo4AlRFwH

Can we cure myeloma before it even starts? 🤯 The CAR-PRISM phase 2 trial just tested cilta-cel in high-risk smoldering myeloma and the results are stunning. 🧬 Study population 20 patients with HR-SMM No induction. No bridging. Pure CAR-T strategy 💉 Trial design https://t.co/8tLQq8mhzH https://t.co/qfqfLu3zD3

Immunoprevention continues to gain momentum as O. Nadeem shares, “Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trial” at #AACR26. A #JITC position article from @sitcancer explores key challenges and opportunities in this evolving space: https://t.co/fGDt1aaEQa

Proud to share results from our CAR-PRISM trial of cilta-cel in HR-SMM published @NatureMedicine and presented at #AACR @IrenemGhobrial @DavidCdSMD @DanaFarber #mmsm https://t.co/9qJiDWGsrK

At the #AACR26 press conference, @OmarNadeemMD of @DanaFarber presents results of the phase 2 CAR-PRISM clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma. The study also published today at @NatureMedicine: https://t.co/FpadmhMjvC

@OmarNadeemMD presenting at #AACR26 CAR-PRISM. 100% ORR & MRD neg., no progression at median FU of 15.3 mo. No high-grade CRS, IEC-HS, CAR T enterocolitis, delayed heme tox. or 2nd malignancies. NINTs in 7 patients; 4 resolved completely. Strong results! #mmsm @IrenemGhobrial https://t.co/BnucCM2alK

At #AACR26: Results from CAR-PRISM Trial. @OmarNadeemMD says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration." @DanaFarber ➡️https://t.co/YWzAIgM3ht https://t.co/X4SrTWlsCF

#Myeloma Paper of the Day: CAR-PRISM phase 2 trial of Ciltacabtagene autoleucel in high-risk smoldering myeloma finds all patients achieved MRD negativity 10-6 by 2 mos & have remained negative; CRS in 100%, non-ICANS neurologic toxicities in 35%: https://t.co/5unLUHp1R6. #mmsm https://t.co/4Y3vrcH2MH

Excited to see CAR-PRISM presented at #AACR26 and published in Nature Medicine. Grateful to have contributed—thanks to @OmarNadeemMD and @IrenemGhobrial for the leadership and opportunity. Pushing the boundaries of early interception. More to come. https://t.co/uAUUY67yUq https://t.co/XyYjMpuLyl

BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering myeloma, according to results from the phase II CAR-PRISM trial reported by @OmarNadeemMD at #AACR26. https://t.co/tG3phqzCaZ @danafarber @harvardmed https://t.co/tY69cB16VG

Looking forward to the results of the CAR-PRISM trial presented in Hall H this morning @OmarNadeemMD ⁦@IrenemGhobrial⁩ #mmsm #AACR26 https://t.co/lpcMB9VyqM

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial. @OmarNadeemMD @DanaFarber @AACR #AACR26 #mmsm #hematology https://t.co/86fFIjmeRK

Results of phase 2 CAR-PRISM trial now out @NatureMedicine. Excited to be part of this huge effort. Congratulations to all especially @OmarNadeemMD and @IrenemGhobrial https://t.co/DjlGXiq4bs https://t.co/0BVn6hnNge

Could the use of CAR T-cell therapy achieve MRD-negative smoldering myeloma without induction therapy? At #AACR26, Omar Nadeem, MD (@OmarNadeemMD @danafarber) presents results from the CAR-PRISM trial. Key takeaways: • This is the first study of CAR T-cell therapy in a https://t.co/KrsGAyjusX

Omar Nadeem shared findings from the CAR-PRISM trial evaluating ciltacabtagene autoleucel in high-risk smoldering myeloma during the third Clinical Trials Plenary at #AACR26. Read the full recap in AACR Annual Meeting News: https://t.co/euYQYYGoKS https://t.co/epmDDd7uRC

#MMSM The CAR-PRISM: Cilta-cel in high-risk smoldering myeloma @NatureMedicine @OmarNadeemMD https://t.co/5XVn3F56O7 ➡️N=20, Single infusion cilta-cel (n=7 with 0.3 mil cells/kg), No induction or bridging ➡️100% MRD negativity (10⁻⁶) by 2m ➡️No progression or deaths (median Fu https://t.co/Vuroejs3As

CAR-PRISM: Cilta cel in smoldering myeloma #mmsm @NatureMedicine ➡️ https://t.co/KLjHDiSuTO ✅n=20 patients ✅ 1ry endpoint: dose limiting toxicities+ treatment emergent adverse events (I.e: safety) 🧵 with important observations https://t.co/lJSba2IrJb

The CAR-PRISM study is now in published today online in Nature Medicine #AACR26 @OmarNadeemMD @IrenemGhobrial #mmsm https://t.co/0Uob7yqUE2

@AACR Top Trials from Day 4 RMC-9805-001 | CAR-PRISM | CLOVER | INFINITY | D3S-001-100 | NCI-2018-01297 | CheckMate 77T | BP42675 | SHR-1316-III-303 | NCT06237881 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL https://t.co/9P4Lis53eX

@Papa_Heme The advancement of CAR-T therapy, particularly through trials like CAR-PRISM with ciltacabtagene autoleucel, represents a promising approach in treating high-risk smoldering multiple myeloma. It's fascinating how these therapies might potentially be applied to MGUS, given its

@MoffittNews @OmarNadeemMD @DanaFarber The exploration of CAR T-cell therapy for achieving MRD-negative status in smoldering myeloma without induction therapy is an intriguing area of research. It's encouraging to see the results from the CAR-PRISM trial being presented. In your observations from #AACR26, what

Game-changing data from AACR 2026: all 20 patients in the CAR-PRISM trial treated with Carvykti for high-risk smoldering multiple myeloma reached undetectable disease levels within two months. https://t.co/OgtlIiLo8l #MultipleMyeloma #CART #AACR2026 #BloodCancer #TCSC

@DrRishabhOnco The promising results from the CAR-PRISM phase 2 trial raise a fascinating question about the potential prevention of myeloma. Given the trial's focus on high-risk smoldering myeloma with cilta-cel, do you think this approach could redefine earlier treatment paradigms in

#AACR26 New frontiers in oncology 🚀 📌 Elisrasib 2/3L #NSCLC #KRASG12C 🗣️@cbcbc1971 ✔️ ORR 59.5% 2L naive ✔️ ORR 32.3% 3L refractari 🎯 KRASampl ORR 60% 🎯 STK11/KEAP1mut ORR 55 vs 71% 😀 New player #KRASG12C 🚀 Going to 1L in comb CT+IO 🗣️By @DocSacher @OncoAlert @AACR https://t.co/SOZdRu2Sr8

Dr. Byoung Chul Cho presented elisrasib (D3S-001), next gen KRAS G12C inhibitor in NSCLC at #AACR26. Images not posted by request. In 84 pts with no prior G12C inhibitor, RR 59.5%, DCR 98.8%, PFS 9.4m. In pts with prior G12Ci, RR 32.3%, DCR 83.9% DOR 15.6, PFS 8.1m. ctDNA https://t.co/LE924qG9Qc

Exciting data presented by @cbcbc1971 @yonsei_u on elisrasib (D3S-001), a next-gen KRAS G12C inhibitor in advanced #NSCLC: ➡️G12Ci-naïve: Observed response rate 73.5%, with durable responses seen out to 3+ years ➡️G12Ci-refractory (600mg QD): ORR ~31%, with 8 pts (25%) still on https://t.co/xTDN9ZDr2H

Encouraging results from #AACR26 on Elisrasib (D3S-001) for KRAS G12C NSCLC by Dr. Cho 🧬 Key highlights: ✅ 2L+ G12Ci Naïve: 59.5% ORR, mDOR 14.9 months. ✅ 3L+ G12Ci Refractory: 32.3% PR rate, mDOR 15.6 months. ✅ Mechanism: CNS penetrable; overcomes resistance in https://t.co/h0HXr3557c

Attending the #AACR26 Clinical Plenary on New Frontiers in Precision Oncology? ICYMI: D3S-001 Shows Robust Preclinical and Clinical Activity https://t.co/rCMwBo50lK By session speaker Byoung Chul Cho @cbcbc1971 and colleagues https://t.co/FPM3D7plTj

Byoung Chul Cho shared updated phase I/II clinical trial results evaluating elisrasib in patients with locally advanced or metastatic NSCLC at #AACR26. Learn more in AACR Annual Meeting News: https://t.co/zDWUL0UnRx https://t.co/TCOveOTo9M

Responses to elisrasib were seen both in patients who were naïve for KRAS G12C inhibitor therapy and in those whose disease progressed on prior KRAS G12C inhibitors. #AACR26

elisrasib does not have a partner yet and zoldonrasib targets G12 D 4% of NSCLC and most common PDAC. https://t.co/pz80fJns0h

🆕 Next-gen KRAS G12C inhibitor elisrasib induced: ➡️ Tumor shrinkage in 60% (resistant pts) ➡️ Molecular responses in most pts with KRAS G12C+ NSCLC High target engagement translating clinically. 🗣️ Presented by Byoung Chul Cho, MD, PhD at #AACR26 🔗 https://t.co/M3nu8d7FFC https://t.co/4CE8iv0alW

Impressive data on #nextgen #KRAS G12C inhibitor, Elisrasib, at #AACR26. ORR 73.5% with durable responses to >= 3y in treatment naive population! #LCSM @yonsei_u https://t.co/lEyYChUsru

🧬 Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC? 👉VIDEO: https://t.co/CrIuzCwkaZ Recent data presents alisertib (elisrasib) as a potent option for both G12C-naive and refractory NSCLC patients. 🚀 Key Clinical Data: ✅ 52.9% ORR in https://t.co/YDjuBpVK03

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR Top Trials from Day 4 RMC-9805-001 | CAR-PRISM | CLOVER | INFINITY | D3S-001-100 | NCI-2018-01297 | CheckMate 77T | BP42675 | SHR-1316-III-303 | NCT06237881 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL https://t.co/9P4Lis53eX

@DrMirallas @cbcbc1971 @DocSacher @OncoAlert @AACR Mesmerizing developments at #AACR26 indeed! It's interesting to see how Elisrasib is performing across different line therapies. ORR variations between 2L naive and 3L refractory, as well as the KRAS amplification impact, raise some intriguing implications for treatment

🫁 Elisrasib showed “robust and durable efficacy” in patients with previously treated locally advanced or metastatic KRAS G12C NSCLC, according to results from an ongoing phase 1/2 trial presented at #AACR26 by @cbcbc1971. ➡️ Read more: https://t.co/wMOlsArHKg #lcsm #NSCLC https://t.co/DXrgvWDQXw

@christine_lovly @yonsei_u This 3+ year durability data marks a paradigm shift for advanced NSCLC. I consider Elisrasib's efficacy clear proof that sustained precision medicine investment in robust innovation ecosystems delivers lasting impact. #AACR26

News: Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC https://t.co/jiT2vXDcJx https://t.co/xwjnHO1tmh

Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer https://t.co/8PN4eTj1ta https://t.co/J7HgQWE1TV

@youngkwangchae Impressive data on Elisrasib (D3S-001)! The mechanism of CNS penetration is particularly intriguing and suggests potential in tackling resistance for NSCLC patients. How might these results influence future treatment protocols for KRAS G12C NSCLC across earlier lines of therapy?

#AACR26 Looking forward to unveiling the first set of results on the👇🏽phase-2 study! We call it the CLOVER☘️Trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen 💡Building upon options for our patients with #ColorectalCancer. @OncoAlert https://t.co/4n7nWZO7oG

#AACR26 Come to our session 🪧 tomorrow. We call it the CLOVER☘️Trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen 📍2-5 PM 💡Building upon options for our patients with #ColorectalCancer. @OncoAlert @cityofhope https://t.co/PLx60BGKP8

💡The fascinating part is how a drug (💉◼️Leronlimab) in latter phases of development for treatment of HIV🦠is helping T-cells fight cancer 🦀. Specially focusing on pMMR/MSS “cold” 🧊 #ColorectalCancer. #AACR26 @AACR ◼️CLOVER☘️Trial link: 🔗 https://t.co/1QNjLtdbpG https://t.co/96I23p76yP

#AACR26 🔖 2-5 pm today 📍Section 4️⃣1️⃣ 🪧Poster 1️⃣4️⃣ @OncoAlert CLOVER☘️Trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen #ColorectalCancer https://t.co/JAulklVwCR https://t.co/2ArLV3RSPH

#AACR26 Excited & honored to unveil initial results from the phase-2 CLOVER ☘️ trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen 🏃‍♂️to our session 🔖 2-5PM 📍Section41🪧Poster14 👇🏽Promising #ctDNA💦📉 MSS #ColorectalCancer @OncoAlert https://t.co/t1hfQuUMTO

🧪 Leronlimab (anti-CCR5) FTP/TPI+BEV in rmCRC (#AACR2026, 6466) 📊 Phase II ongoing (n=10) 🔹 100% CCR5 expression 🔹 Early ↓CEA/CA19-9/ctDNA (4/4 pts in one site) 🔹 ↑PD-L1, ↓CTCs/CAMLs 🔹 Safety: no unexpected signals 💥 CCR5: emerging immunomodulatory target 🔗

#AACR26 🎤 drop. Unveiling our first results @AACR—CLOVER ☘️ trial enrollment is COMPLETE. 6️⃣0️⃣/6️⃣0️⃣ 💯% started treatment. Record-pace accrual. Grateful to our patients, caregivers, study teams, & sponsor. Important milestone! 🔗 🗞️ 👏🏽 @OncoAlert https://t.co/ktqqWCNuc8 https://t.co/VO8fiwhKpX

Today at #AACR26: @pashtoonkasi, medical director of GI oncology at @cityofhopeoc , will share breakthrough findings from the Clover Trial. Stop by Section 41, Poster 14, between 2 to 5 p.m. to learn more! #colorectalcancer https://t.co/hr5wnTcrWg

#AACR26 | Gyn Onc #MYTHIC trial (CT022) - first-in-human data for #WEE1i #zedoresertib + #PKMYT1i #lunresertib in genomically selected solid tumors (#CCNE1 amp, #FBXW7 mut, #PPP2R1A mut). These alterations drive replication stress and have NO approved targeted therapy - 24.5% of https://t.co/sM2DhABeo8

#AACR26 New frontiers in oncology 🚀 📌 Zedoresertib+Lunresertib #CCNE1 #FBXW7 #PPP2R1A 🗣️Dr.Yap @UTMDAnderson ✔️ ORR 25% if #CCNE1 ✔️ Ovarian ORR 50% at MTD2, if #CCNE1 60% ✔️ 31% on trial >16w ☣️ Rash, fatigue, N/V 🗣️Dr. Moore @StephensonCC 👉🏼 Optimal dose @OncoAlert @AACR https://t.co/JzrI7CeKy2

At #AACR26, Timothy Yap, MBBS, PhD (@UTMDAnderson) presents Phase I data of the combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. Key takeaways: • First https://t.co/zuvhtbdvlO

The results showed early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors with these alterations. Read more: https://t.co/QZjWiT396o (2/2) #EndCancer

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer https://t.co/8Vt4Z3qcAK Learn more 👉 https://t.co/C4ftOyCpsu https://t.co/s0FzIRDxIM

@DrMirallas @UTMDAnderson @StephensonCC @OncoAlert @AACR The exploration of Zedoresertib and Lunresertib looks promising, especially with noteworthy response rates in #CCNE1 cases. The safety profile noted is crucial for understanding broader applicability. How do resistance mechanisms play into long-term efficacy, and what's the

Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough? https://t.co/cnCwNRe9Hi Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk. #Debiopharm #Lunresertib

Data from the phase 2 MATISSE trial from @barlesi at #AACR26: perioperative IPH5201 (CD39 inhibitor) + durvalumab + neoadjuvant chemotherapy for resectable NSCLC. Will targeting the adenosine pathway improve pCR? https://t.co/4U2pfaCl0E

Innate Pharma 🔬 MATISSE (#AACR2026). IPH5201 (anti-CD39) + Durva + chimio en NSCLC opérable : ➡️ pCR 35.7% vs 21.2% (AEGEAN) chez PD-L1≥1% ➡️ pCR 50% vs 27.5% chez PD-L1≥50% IPH5201 pourrait fortement booster Durvalumab Biomarqueur CD39+ identifié $ipha https://t.co/wgUGE795PD

#AACR26 The adenosine pathway is an appealing target given its immunosuppressive role. IPH5201 targets CD39 and has in vitro synergy with chemo-immunotherapy. MATISSE leverages that synergy with a combination of perioperative IPH5201 and durvalumab added to neoadjuvant chemo. https://t.co/SXL0HbL1pD

Innate Pharma to present Phase 2 MATISSE interim data of IPH5201 + durvalumab in NSCLC at AACR 2026 #innatepharma #iph5201 #nsclc #immunotherapy #aacr2026 #cd39 #durvalumab #clinicaltrials #oncology https://t.co/Wkme6tBYWu

#AACR26 In MATISSE, need to acknowledge the heterogeneity and going forward, should we distinguish N2 vs non-N2? pCR rates of IPH5201 + durva/chemo encouraging, esp in PDL1 high - not far from current options but smaller sample, single arm. https://t.co/It24B5NNZC

$NUVL Truist NUVL, Buy) Zidesamtinib - Robust activity in post‑TKI settings supportive of the initial TKI-pretreated positioning. NUVL's new ph.I/II ARROS‑1 clinical and preclinical data support zidesamtinib’s (zide) activity in heavily pre‑treated (85–90% ≥2 prior ROS1 TKIs;

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 $NUVL https://t.co/GFb5B9BhAl

$NUVL - New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 News & Disclaimer https://t.co/T4nuhXfQgC

$NUVL New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 https://t.co/CHaB94BUP4

$NUVL New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 More Info: https://t.co/8qNjyc8II1 https://t.co/vCKy3hu1R4

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 $NUVL https://t.co/zefTlRpitf

Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data https://t.co/C2NxQadlAD #Nuvalent #NUVL #AACR2026 #LungCancer #NSCLC #Biotech #Oncology #ROS1 #CancerResearch #PrecisionMedicine

🫁📊Strong NSCLC Trial Results Nuvalent reports encouraging trial data for zidesamtinib in NSCLC, reinforcing progress in targeted cancer therapies. 👉 https://t.co/fsT9uwluhn #Oncology #NSCLC #ClinicalTrials #Biotech https://t.co/Q9aHbKm9Uv

China’s NMPA approved GSK’s anti-BCMA ADC Blenrep (belantamab mafodotin). The drug is approved in combination with bortezomib and dexamethasone for adult patients with multiple myeloma who have received ≥1 prior therapy.

🚨 News 🚨 China’s NMPA approves belantamab mafodotin in combination with bortezomib + dexamethasone for the treatment of adults with relapsed/refractory #MultipleMyeloma after ≥1 prior LoT; based on phase III DREAMM-7 results. Read more: https://t.co/IylZ1nx8xD #myeloma https://t.co/ZySMGVANPo

#GSK Blenrep (belantamab mafodotin) approved in China with a Bortezomib and Dexamethasone combo for treating Adults with a form of multiple myeloma.

🌏 Belantamab mafodotin + bortezomib/dexamethasone (BVd) has been approved in China for R/R multiple myeloma, backed by phase 3 DREAMM-7 data showing significant PFS and OS improvements vs DVd. 📊 Read more ➡️ https://t.co/aEquzGI8M7 #MultipleMyeloma #HemeOnc #TargetedTherapy

China’s NMPA has approved belantamab mafodotin plus bortezomib and dexamethasone for adults with relapsed/refractory multiple myeloma following 1 or more prior lines of treatment. https://t.co/vsGnncNoMZ #mmsm #Myeloma #Oncology #Cancer https://t.co/dSHWedHQOP

⚡ #GSK ↗️ AI digest + live charts: https://t.co/wgK3SSZhaY 🧠 AI pulse: The approval is based on the DREAMM-7 trial, which showed a 42% reduction in death risk and nearly tripled median progression-free survival compared to a daratumumab-based triplet | The approval follows

🚨 Latest #Oncology Update! 🔷 Blenrep (Belantamab mafodotin) has been approved in China for the treatment of patients with relapsed/refractory multiple myeloma who have received two or more prior lines of therapy. This approval expands access to a novel BCMA-targeted therapy https://t.co/jIZkbltOZU

Exciting news! 🎉 GSK's Blenrep approved in China for refractory multiple myeloma. 🇨🇳 Promising data from Dreamm-7 trial, offering hope to patients. 🌟 #GSK #Blenrep #MultipleMyeloma #GSK

Series Daratumumab - the new frontline for multiple myeloma Belantamab mafodotin - the new antibody drug conjugate for refractory multiple myeloma

Big Comeback Story 🚀 GSK’s BCMA ADC returns—now approved in China for multiple myeloma. Belantamab mafodotin is a BCMA-targeted ADC, supported by Phase III results from DREAMM-7 showing improved survival outcomes. A new option enters the growing BCMA treatment landscape. 📌 https://t.co/ndNdggjE5f

MedJ Approval: NMPA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma in China China has cleared the BCMA-directed ADC with bortezomib and dexamethasone after phase 3 DREAMM-7 showed major PFS and OS gains. Full Article from https://t.co/shU3d9B3pj

#GSK’s BCMA ADC returns—now approved in China for #multiplemyeloma. #BelantamabMafodotin is a #BCMA-targeted ADC, supported by Phase III results from DREAMM-7 showing improved survival outcomes. 📌 For informational purposes and not medical advice. #DengYueMed #ChinaApproval https://t.co/M9tsr7R3s0

Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed https://t.co/oZzAU4ndpi

Phase 1b/2 ZL-1310 (DLL3 ADC) in pretreated NECs presented by @rohit_thum at #AACR26 : ORR 38.2% (13/34), responses across multiple primaries.TEAEs in 97.8%, G3+ ~30% (mostly GI/heme). DLL3 H-score not clearly predictive!! Encouraging results especially with some durable https://t.co/QR2yFjoF4K

Marie Evangelista of Circle Pharma finally disclosing the structure of CID-078, a macrocyclic peptidomimetic cyclin A/B inhibitor to treat cancers with Rb loss or E2F hyperactivation. Of note, the apparently high fraction absorbed for such a bRo5 peptidic molecule. #AACR26 https://t.co/WF6WOexdHP

$CHRS A competitor to tagmokitug; Gilead's CCR8 denikitug just posted a new phase 2 trial in CRC a few days ago. https://t.co/9Xg5RxbDHB Gilead will also be presenting preliminary phase 1 data on denikitug at AACR in a few days on April 21st. https://t.co/1aNt2exc3Y

THREAD #CCR8 What else do we know, going into #AACR26, about anti-CCR8 tox beyond the S-531011 results? Not much. $ONC terminated their trial, but not due to tox. $AMGN and Bayer curtailed their trials but didn't terminate them ("active, not recruiting"). Nothing "acute" looking. https://t.co/HOhsLU3vew

Arrrrgggghhhh! Denikitug results at #AACR26 are monotherapy only! No grade 4 or 5 TRAEs. "In the efficacy evaluable population (n = 52), objective response rate was 8%". $GILD $CHRS #CCR8 https://t.co/j6pD4mHuCw

New trial, but sort of boring. $GILD #CCR8 #denikitug with either bevacizumab or nivolumab in MSS CRC.... https://t.co/Zfrt6NRBXU

@MoffittNews @BrunoBockorny @BIDMChealth This sounds like a promising development in the treatment of advanced solid tumors. Could you share more about how the anti-CCR8 antibody denikitug specifically works to target these tumors, and what the preliminary results tell us about its safety and efficacy? It's exciting to

#AACR26 @AACR · The KRAS story is reorganizing. Reading @HartungIngo (Day 1 highlight) + @DrMirallas (Ambrogio live capture) together — Day 1 KRAS signals seem to organize around three paths: 1/ ON + OFF together Sotorasib/adagrasib lock the OFF (GDP-bound) state. Resistance

#AACR26 💥 Risvutatug rezetecan (B7H3-TOPI) + Abebrelimab (PD-1) 🗣️Dr. Zhong 🚀 ARTEMIS-101 (n=253) 🫁 NSCLC (ADK) no AGA ✔️ ORR 47.1% ✔️ mPFS 14m ⬆️ 14pts >12m ☣️ Bone marrow 👉🏼 Promising activity of #ADC and #ICI #NSCLC 🗣️ @MLJohnsonMD2 @SarahCannonDocs 👏🏼great @OncoAlert https://t.co/PzdErupaT0

@DrMirallas @MLJohnsonMD2 @SarahCannonDocs @OncoAlert The combination of Risvutatug rezetecan and Abebrelimab showing a 47.1% ORR and 14 months mPFS in NSCLC is indeed impressive. It highlights the potential synergy between ADCs and ICIs in enhancing treatment outcomes. It would be intriguing to delve into the specific mechanisms by

MSK research tech Abraham Meyerson’s poster about “Integrating padeliporfin vascular-targeted photodynamic therapy with enfortumab vedotin and immune checkpoint blockade in urothelial cancer models” at #AACR26. @aacr https://t.co/ofwHIyfM6X

@jonchou05 delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder cancer. @UCSFCancer #AACR26 The takeaways: https://t.co/9VhkyZ4etc

ctDNA is changing how we treat colon cancer. This video explains the DYNAMIC III trial and how ctDNA helps decide who needs chemotherapy and who doesn’t. Watch here: https://t.co/lM07ysUrtK

Not every stage III colon cancer patient needs the same chemotherapy. The DYNAMIC III trial shows how ctDNA can personalize treatment decisions after surgery. https://t.co/GZZk4o1bdG

$BBOT - BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 https://t.co/MmDlX6JHW7

“BridgeBio Oncology KRAS, BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer.” $BBOT #AACR26 https://t.co/BGvJtBYRAT

BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer. $BBOT #AACR26 https://t.co/Jq5MIaYuf1

$BBOT BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition

$BBOT's preclinical data at AACR 2026 reveals BBO-10203, a RAS:PI3Kα breaker that allosterically disrupts the interaction to inhibit PI3Kα/AKT signaling in HER2AMP models without kinase inhibition or hyperglycemia, showing strong in vivo combo

Tebentafusp yielded a favorable 5-year survival rate vs investigator’s choice of therapy in HLA-A*02:01-positive uveal melanoma. ⬇️ Read for more on the phase 3 IMCgp100-202 study ⬇️ https://t.co/K6YXEB4V4Q #melsm #Melanoma #AACR26

🧬 Durable survival gains continue with tebentafusp in uveal melanoma. Long-term follow-up confirms a sustained OS benefit with tebentafusp in HLA-A*02:01–positive metastatic uveal melanoma, with improvements maintained out to 3–5 years vs investigator’s choice therapy. 📊 Read

Updated 5-year data show that tebentafusp (KIMMTRAK) helps patients with metastatic uveal melanoma live longer than other treatments. Notably, twice as many patients were alive at five years. https://t.co/ORfttFoDA3 https://t.co/pEFcAtVzWq

New 5-year data for tebentafusp in metastatic uveal melanoma is here! 🧬 Highlights from @AACR: ✅ Durable survival benefit (21.6 vs 16.9 months) ✅ 81% overall molecular response rate ✅ 46% disease control rate Watch the full interview! 👇 https://t.co/3RpkKmFz9a https://t.co/a0fSlrYZjx

New 5-year data for @Immunocore's tebentafusp-tebn set new standards for long-term survival in metastatic uveal melanoma. Explore how TCR-based bispecifics and ctDNA could transform your strategy: https://t.co/f0yy2Ssohu #ImmunoOncology #OncologyInnovation #TCRTherapy #ctDNA https://t.co/IbO8fjVX3f

Daraxonrasib (RMC-6236), a promising pan-RAS inhibitor from @RevMedicines, vs docetaxel trial in KRAS mutant NSCLC is ongoing. Great to see Dr. @FSkoulidis at #AACR26 https://t.co/I5NYYTglZr

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR : Top Trials from Day 2 RASolute 303 | RMC-6236-001 | CheckMate 77T | INFINITY | NeoZanHER | SHR-1316-III-303 | PLN-101095-ONC-101 | GBG-96-GeparDouze | NCT06131398 | DKY709A12101C #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter https://t.co/ol7y77fDl5

@StephenVLiu @ThomasW35874311 @AACR I note the robust EFS benefit (HR 0.52) with perioperative adebrelimab. The MPR/pCR improvements and ctDNA correlation provide clinically meaningful support for neoadjuvant protocols. #AACR26

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR : Top Trials from Day 2 RASolute 303 | RMC-6236-001 | CheckMate 77T | INFINITY | NeoZanHER | SHR-1316-III-303 | PLN-101095-ONC-101 | GBG-96-GeparDouze | NCT06131398 | DKY709A12101C #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter https://t.co/ol7y77fDl5

@NotGenentech Yeah, but AMGN will be reporting tomorrow on largest patient sample to date, 30 anti-#ccr8 (AMG 155) plus pembro. Safety OK, zip for efficacy. CHRS had small, solid tumor sample and "failed" at 1/7 responses. Bayer and ZLAB packed bags. BMY flailing in dark.

@ForPlanetPluto @jfais20 Question... have you told your substack readers what you think the opening share price might be, Monday's open after the $AMGN AMG 155 presentation at #AACR26?

MiNK Therapeutics reported Phase II data in PD-1 refractory gastroesophageal cancer at #AACR2026. In the first study of agenT-797 + #BOT/BAL in this setting, treatment achieved 77% disease control, with induction linked to longer PFS and durable survival in a subset, alongside https://t.co/eUiBKXuSv7

“Puma presentation of updated data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (Q4 2026).” $PBYI #AACR26 https://t.co/aDhHSVVn3X

“Puma Presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (Q2 2026).” $PBYI #AACR26 https://t.co/aDhHSVVn3X

@AACR Top Trials from Day 3 RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355 #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX https://t.co/cZGznoUzDP

@AACR : Top Trials from Day 2 RASolute 303 | RMC-6236-001 | CheckMate 77T | INFINITY | NeoZanHER | SHR-1316-III-303 | PLN-101095-ONC-101 | GBG-96-GeparDouze | NCT06131398 | DKY709A12101C #AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter https://t.co/ol7y77fDl5

@Wildingarden In the Phase 3 DESTINY-Breast05 trial (EudraCT 2020-003982-20, the one authorized in Ireland in 2021 for Daiichi Sankyo’s trastuzumab deruxtecan vs. T-DM1), there were two adjudicated Grade 5 (fatal) interstitial lung disease events in the T-DXd arm. These were the only

@Wildingarden The specific hospitals where the two adjudicated Grade 5 (fatal) ILD events occurred in the T-DXd arm of DESTINY-Breast05 are not publicly disclosed in the NEJM publication, https://t.co/0AwSOt0GMS (NCT04622319), or related trial materials. Patient-level details like exact

Combining ramucirumab with pembrolizumab did not improve OS vs SOC for patients with previously treated stage IV or recurrent NSCLC. ⬇️ For more from the phase 2 SWOG S2302 PRAGMATICA-LUNG trial ⬇️ https://t.co/WSFV7v5NVj #lcsm #NSCLC #AACR26 #oncology | @ReckampK

Dr. Sheheryar Kabraji (@RoswellPark) draws a critical parallel: these findings mirror #DESTINYBreast09 data in HER2+ breast cancer — where T-DXd in earlier lines preserved or improved efficacy. This is precision oncology in action. @SABCS_ #BreastCancer #HER2positive #AACR2026